Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • Acazicolcept (ALPN-101)
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  management team  |  documents  |  committee composition  | 

  • May 18, 2021
    Summary ToggleAlpine Immune Sciences Announces Oral Presentation at the 2021 EULAR Virtual Meeting
    SEATTLE --(BUSINESS WIRE)--May 18, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an oral presentation of preclinical data from the
    Read More
  • May 13, 2021
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results
    SEATTLE --(BUSINESS WIRE)--May 13, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the
    Read More
  • April 28, 2021
    Summary ToggleAlpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting
    SEATTLE --(BUSINESS WIRE)--Apr. 28, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an upcoming presentation on NEON-1, the company’s Phase
    Read More
  • April 12, 2021
    Summary ToggleAlpine Immune Sciences Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I
    – NEON-1, clinical trial with ALPN-202 monotherapy, proceeds through dose escalation – – New discovery efforts yield novel preclinical fusion proteins that enable tumor antigen-dependent CD28 costimulation – SEATTLE --(BUSINESS WIRE)--Apr. 12, 2021-- Alpine Immune Sciences, Inc.
    Read More
  • March 18, 2021
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
    - Conference call and webcast today at 4:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Mar. 18, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a
    Read More
  • March 11, 2021
    Summary ToggleAlpine Immune Sciences to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
    SEATTLE --(BUSINESS WIRE)--Mar. 11, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release fourth quarter and full year
    Read More
  • March 10, 2021
    Summary ToggleAlpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I
    SEATTLE --(BUSINESS WIRE)--Mar. 10, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the planned presentation of two posters at the American
    Read More
  • February 22, 2021
    Summary ToggleAlpine Immune Sciences to Participate in Upcoming Virtual Healthcare Conferences
    SEATTLE --(BUSINESS WIRE)--Feb. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate at the Cowen 41st Annual
    Read More
  • January 6, 2021
    Summary ToggleAlpine Immune Sciences Announces Executive Leadership Addition and Promotion
    Pamela Holland , Ph.D., Joins as Senior Vice President, Research Remy Durand , Ph.D., Promoted to Chief Business Officer SEATTLE --(BUSINESS WIRE)--Jan. 6, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments
    Read More
  • December 17, 2020
    Summary ToggleAlpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
    SEATTLE --(BUSINESS WIRE)--Dec. 17, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the 39th Annual J.P.
    Read More

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last
Displaying 31 - 40 of 136 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2022 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Management Team
    • Documents
    • Committee Composition